



## NeuroMetrix Reports Publication of New Clinical Studies on DPNCheck

June 26, 2018

WALTHAM, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of three new clinical studies on DPNCheck<sup>®</sup>, a point-of-care device that provides accurate and cost-effective screening, diagnosis, and monitoring of diabetic peripheral neuropathy (DPN).

- Diabetic Medicine - [One-stop microvascular screening service: An effective model for the early detection of diabetic peripheral neuropathy and the high-risk foot. \(Binns-Hall, et. al.\)](#)
- PLoS ONE - [Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. \(Scarr, et. al.\)](#)
- Journal of Diabetes Investigation - [Difference in normal limit values of nerve conduction parameters between Westerners and Japanese people might need to be considered when diagnosing diabetic polyneuropathy using a Point-of-Care Sural Nerve Conduction Device. \(Hirayasu, et. al.\)](#)

Binns-Hall's study of 236 patients assessed the feasibility of assessing diabetic patients for neuropathy during routine diabetic eye exams in community clinics. The authors concluded that adding neuropathy screening with DPNCheck to a retinal screening clinic was feasible and had a high patient acceptability and uptake (91% of favorability among patients). This may be an effective model for the early diagnosis of diabetic peripheral neuropathy and foot complications.

In Scarr's study, the authors looked at the validity of DPNCheck as a proxy for standard nerve conduction studies specifically in the high-risk subgroup of elderly patients with type 1 diabetes. In this 68 patient study, Scarr and colleagues concluded that DPNCheck has strong agreement and diagnostic accuracy for identifying diabetic peripheral neuropathy as compared to standard nerve conduction studies.

Hirayasu's study establishes normal limits for sural nerve conduction velocity and amplitude specifically within a Japanese population. This study should further broaden the clinical acceptance of DPNCheck within the Japanese market.

"We are pleased with the results of these new studies," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "These are excellent additions to the large portfolio of DPNCheck clinical publications and provide further peer-reviewed evidence for the effectiveness and diagnostic utility of the DPNCheck technology."

### About DPNCheck

DPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as diabetic peripheral neuropathy (DPN). It is designed to be used by clinicians at the point-of-care to objectively detect, stage, and monitor DPN.

### About NeuroMetrix

NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell<sup>®</sup>, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit [NeuroMetrix.com](http://NeuroMetrix.com).

NeuroMetrix, Inc.  
Thomas T. Higgins, 781-314-2761  
SVP and Chief Financial Officer  
[neurometrix.ir@neurometrix.com](mailto:neurometrix.ir@neurometrix.com)

Source: NeuroMetrix, Inc.

 [Primary Logo](#)

Source: NeuroMetrix, Inc.